Securities fraud litigation history and active cases
In Litigation
0
Settlement
0
Closed
2
Total Settlement
$130M
2:17cv11089 • November 3, 2017
Class Period Start
October 29, 2013
Class Period End
November 3, 2016
PSLRA Deadline
May 10, 2017
Case Allegations
10b5
Statutes of Repose
Oct 29, 2016
Country
United States
Court
Federal Court
Oct 28, 2022
Voluntary Dismissal
The plaintiff in this action has chosen not to proceed with the case. Once a case is voluntary dismissed, the courts will usually close the case and no further action will be taken.
Sep 30, 2021
Motion to Dismiss Denied
The court has denied the defendants' request to dismiss the lawsuit. The case can now move forward to the next stage of litigation.
Dec 6, 2019
Motion to Dismiss
After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.
Oct 8, 2019
First Amended Complaint
A new complaint has been filed on behalf of certain investors in Allergan plc. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.
Sep 10, 2019
Scheduling Order
2:16cv9449 • December 22, 2016
Class Period Start
October 29, 2013
Class Period End
January 31, 2017
PSLRA Deadline
January 3, 2017
Case Allegations
10b5
Statutes of Repose
Oct 29, 2016
Country
United States
Court
Federal Court
Please note that for cases in the settlement stage, claims are handled by the claims administrator and NOT Levi & Korsinsky. Any information or documentation previously provided to us does not constitute submission of a claim. If you need to file a claim, check the status of a claim, or have questions regarding distribution of settlement funds, please contact the claims administrator below.
Claim Deadline
December 27, 2021
Settlement Fund
$130,000,000
Settlement Status
Disbursed
Settlement Class
All persons or entities that purchased or otherwise acquired securities during the period between October 29, 2013 and November 2, 2016, both dates inclusive.
Claim Administrator
A.B. Data, Ltd.
Allergan Generic Drug Pricing Securities Litigation
c/o A.B. Data, Ltd.
P.O. Box 173016
Milwaukee, WI 53217
+1 877-777-9328
[email protected]
Settlement Website
http://www.allergandrugpricingsecuritieslitigation.com/Hearing Date
November 17, 2021
Opt-out Deadline
October 27, 2021
Settlement Note
Download hereProof Of Claim
Download here
Dec 27, 2023
Disbursement Approved
The court has approved the distribution of settlement funds to eligible class members. Investors with approved claims may receive payments from the settlement. If you have questions about your claim or payment, contact the claims administrator.
Nov 22, 2021
Final Approval of Settlement
The court has granted final approval of the settlement. Eligible investors who submit valid claims may receive a payment once the claims review and distribution process is completed.
Aug 27, 2021
Proof of Claim Form
To receive your portion of the recovery (if you are eligible), you must submit this form to the claims administrator by the deadline indicated on the form itself. If you do not submit this form in time, you will not be entitled to compensation. If you have questions about how to complete the form, you should contact the claims administrator.
Jul 30, 2021
Preliminary Approval of Settlement
The court has granted preliminary approval of a proposed settlement. This means the settlement can move forward for further consideration, but it has not yet received final approval. Potential class members will generally receive notice explaining the settlement, their rights, and any deadlines for submitting a claim, objecting to the settlement, or choosing not to participate.
Jul 9, 2021
Proposed Settlement
TOP
